So basic healthcare = liver transplants but not breast cancer drugs that extend life?
Oh, sorry. It's successfully feeding and housing 99.8% of all American citizens. Pretty damn good.
Just a few factual errors I wanted to address.
Breast cancer drugs are provided.
The drugs that are not readily provided (right now) by the NHS are the monoclonal antibody therapies.
The majority of these drugs are very new, and they do not work on everyone, and in some cases, they make the person even worse.
You may recall the clinical trial in England that resulted in the death of several of the participants from a cytokine storm. In theory, this is a possible outcome of monoclonal antibody treatment with a tumour marker that the body has never been presented with before.
http://en.wikipedia.org/wiki/TGN1412
Cytokine storms have been implicated in drug therapies, the potential when introducing antibodies from another animal have to be addressed.
http://en.wikipedia.org/wiki/Cytokine_storm
In the case of the breast cancer MaB treatment and basic theory to demonstrate that it will only work on about 30% of women (the clinical trials also support this)
http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy
Examples include ErbB2, a constitutively active cell surface receptor that is produced at abnormally high levels on the surface of approximately 30% of breast cancer tumor cells. Such breast cancer is known a HER2 positive breast cancer
Other issues with monoclonal antibody therapy: Evidence it could make you worse
http://www.medscape.com/viewarticle/709024_5
Monoclonal Antibodies in Multiple Sclerosis Treatment: Generic Problems with Monoclonal Antibodies 3: CNS Penetration
There have also been many reports of induction of brain metastases in women with a good systemic response to trastuzumab for HER-2 positive breast cancer [Lindrud et al. 2003],
Another issue with monoclonal antibody therapy: It could make future diagnosis of a number of clinical issues difficult or almost impossible.
This one is standard laboratory knowledge in the UK.
Antibodies uses for diagnostic and clinical treatment are murine, or from mice.
Currently, people exposed to pets, mice, hamsters and birds, have a tendency to have an odd set of antibodies that are generally called heterophile antibodies (this is not to be confused with the test for mononucleosis/glandular fever).
http://www.clinchem.org/cgi/content/abstract/45/5/616
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553719/
Occurrence and cross-reactivity of heterophile antibodies and anti-kidney antibodies in kidney transplanted patients and patients with renal disease
S. -E. Svehag, R. Olander, and K. -G. Sundqvist
Heterophile antibodies cross react with the antibodies in diagnostic tests (and now, immunoassays account for a phenomenal number of tests from therapeutic drugs, all hormones as well as tumour markers to track the disease), making clinical diagnosis difficult and confused, if not impossible in some cases.
There are issues we may not even be aware of yet. Heterophile antibodies may make things like future treatment impossible.
Monoclonal antibody therapy is currently introducing murine antibodies directly into the body. The potential for forming heterophile antibodies is substantially increased.
These drugs that XJX is claiming are denied in the UK are still currently being studied in numerous clinical trials.
When the drugs cost a phenomenal amount of money and only treat one third of patients with several potential side effects, including death, I for one, cannot see any other manner in not proceeding with caution with this very new medical treatment.
However, as we all know, the emotive appeal of anecdotal evidence is what wins arguments.
